GlassScriptPhysician profile
Alexis Johnson-Maxim
NPI 1083952097
$2,106.50
in general payments reported to CMS, 2019-2025
24 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $446 · 2023: $279 · 2024: $892 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Education: $58.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.47 |
| Education | $58.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $513.76 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inspire Medical Systems, INC. | $490.09 | 2023-2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $372.17 | 2022-2024 | Fasenra |
| Avadel Cns Pharmaceuticals, LLC | $125.00 | 2024 | Lumryz |
| Harmony Biosciences LLC | $124.99 | 2024 | |
| Genzyme Corporation | $81.10 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $74.54 | 2025 | Dupixent |
| Amgen INC. | $42.58 | 2021 | |
| Qol Medical, LLC | $33.35 | 2025 | Sucraid |
| Mallinckrodt Hospital Products INC. | $30.80 | 2022 | |
| Lilly USA, LLC | $29.69 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.98 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.21 | 2022 | |
| Grifols USA, LLC | $17.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.00 | 2021 | |
| Pfizer INC. | $14.96 | 2021 | |
| Mylan Specialty L.P. | $13.89 | 2022 | |
| Almatica Pharma LLC | $13.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.64 | 2024 | Horizant |
| Daiichi Sankyo INC. | $12.79 | 2022 | |
| Eyevance Pharmaceuticals LLC | $11.63 | 2021 | |
| Hikma Pharmaceuticals USA | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Johnson-Maxim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.